Chronic Myeloid Leukemia (CML)

 

PF-04449913 for Hematologic Malignancies (UW09021)
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies

Investigator: Vivian Oehler, M.D,;   Conditions: Hematologic Malignancies;    Status: Closed;   Study ID: NCT00953758

LBH589 with Imatinib Mesylate for CML (2412)
A Phase I Dose Escalation Study of LBH589 in Combination with Imatinib Mesylate for Patients with Chronic Myeloid Leukemia in Cytogenetic Remission with Residual Disease Detectable by Q-PCR

Investigator: Vivian Oehler, MD;   Conditions: Chronic Myeloid Leukemia (CML);    Status: Recruiting;   Study ID: NCT00686218

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (2645)
A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Investigator: Vivian Oehler, MD;   Conditions: Chronic Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01650805